Literature DB >> 8869646

Disulfide stabilization of antibody Fv: computer predictions and experimental evaluation.

Y Reiter1, U Brinkmann, S H Jung, I Pastan, B Lee.   

Abstract

Using molecular modeling technology we have recently identified positions in conserved framework regions of Fvs which can be used to stabilize antibody Fvs by an interchain disulfide bond engineered in between the structurally conserved framework positions of the variable domains of heavy (VH) and light (VL) immunoglobulin chains (disulfide-stabilized Fv; dsFv). The computer model indicated the existence of other potential sites in the framework regions that might be suitable for disulfide bond formation between VH and VL. The possibility of obtaining dsFvs using these positions is evaluated here experimentally by constructing dsFv immunotoxins in which the Fv moiety is fused to a truncated form of Pseudomonas exotoxin. We analyzed the extent of dsFv formation and the activity of the resulting dsFv immunotoxins, and compared various dsFv molecules with the scFv immunotoxin. Our results demonstrate that position H44-L105 is the only one which gives high production yields of active dsFv. All other positions gave either low yields and activity or completely failed to produce active dsFv. With one exception, the formation and activities of the dsFvs corresponded to the C alpha-C alpha distance between the VH and VL positions, with an optimal distance of 5.7 A producing the best dsFv. Distances of 6.0-6.9 A resulted in a low yield of protein that was still capable of binding antigen, whereas distances > 7.0 A resulted in molecules in which dsFv formation was not obtained.

Entities:  

Mesh:

Substances:

Year:  1995        PMID: 8869646     DOI: 10.1093/protein/8.12.1323

Source DB:  PubMed          Journal:  Protein Eng        ISSN: 0269-2139


  20 in total

Review 1.  Generation of recombinant antibodies.

Authors:  S M Kipriyanov; M Little
Journal:  Mol Biotechnol       Date:  1999-09       Impact factor: 2.695

2.  Conjugation of an antibody Fv fragment to a virus coat protein: cell-specific targeting of recombinant polyoma-virus-like particles.

Authors:  K Stubenrauch; S Gleiter; U Brinkmann; R Rudolph; H Lilie
Journal:  Biochem J       Date:  2001-06-15       Impact factor: 3.857

Review 3.  Generation and production of engineered antibodies.

Authors:  Sergey M Kipriyanov; Fabrice Le Gall
Journal:  Mol Biotechnol       Date:  2004-01       Impact factor: 2.695

4.  Fluorescent Citrine-IgG fusion proteins produced in mammalian cells.

Authors:  Alexander K Haas; Christoffer von Schwerin; Daniela Matscheko; Ulrich Brinkmann
Journal:  MAbs       Date:  2010-11-01       Impact factor: 5.857

Review 5.  The use of single chain Fv as targeting agents for immunoliposomes: an update on immunoliposomal drugs for cancer treatment.

Authors:  W W Cheng; T M Allen
Journal:  Expert Opin Drug Deliv       Date:  2010-04       Impact factor: 6.648

6.  Engineering anti-vascular endothelial growth factor single chain disulfide-stabilized antibody variable fragments (sc-dsFv) with phage-displayed sc-dsFv libraries.

Authors:  Yi-Jen Huang; Ing-Chien Chen; Chung-Ming Yu; Yu-Ching Lee; Hung-Ju Hsu; Anna Tung Ching Ching; Hung-Ju Chang; An-Suei Yang
Journal:  J Biol Chem       Date:  2010-01-12       Impact factor: 5.157

7.  Development of tetravalent, bispecific CCR5 antibodies with antiviral activity against CCR5 monoclonal antibody-resistant HIV-1 strains.

Authors:  Jürgen Schanzer; Andreas Jekle; Junichi Nezu; Adriane Lochner; Rebecca Croasdale; Marianna Dioszegi; Jun Zhang; Eike Hoffmann; Wilma Dormeyer; Jan Stracke; Wolfgang Schäfer; Changhua Ji; Gabrielle Heilek; Nick Cammack; Michael Brandt; Pablo Umana; Ulrich Brinkmann
Journal:  Antimicrob Agents Chemother       Date:  2011-02-07       Impact factor: 5.191

8.  Preclinical evaluation of a novel CEA-targeting near-infrared fluorescent tracer delineating colorectal and pancreatic tumors.

Authors:  Martin C Boonstra; Berend Tolner; Boudewijn E Schaafsma; Leonora S F Boogerd; Hendrica A J M Prevoo; Guarav Bhavsar; Peter J K Kuppen; Cornelis F M Sier; Bert A Bonsing; John V Frangioni; Cornelis J H van de Velde; Kerry A Chester; Alexander L Vahrmeijer
Journal:  Int J Cancer       Date:  2015-06-22       Impact factor: 7.396

9.  Bispecific digoxigenin-binding antibodies for targeted payload delivery.

Authors:  Silke Metz; Alexander K Haas; Karin Daub; Rebecca Croasdale; Jan Stracke; Wilma Lau; Guy Georges; Hans-Peter Josel; Sebastian Dziadek; Karl-Peter Hopfner; Alfred Lammens; Werner Scheuer; Eike Hoffmann; Olaf Mundigl; Ulrich Brinkmann
Journal:  Proc Natl Acad Sci U S A       Date:  2011-05-02       Impact factor: 11.205

10.  Stabilization of human immunodeficiency virus type 1 envelope glycoprotein trimers by disulfide bonds introduced into the gp41 glycoprotein ectodomain.

Authors:  M Farzan; H Choe; E Desjardins; Y Sun; J Kuhn; J Cao; D Archambault; P Kolchinsky; M Koch; R Wyatt; J Sodroski
Journal:  J Virol       Date:  1998-09       Impact factor: 5.103

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.